GlassScriptPhysician profile
Todd Joseph Sheppard
NPI 1033156336
$3,333.71
in general payments reported to CMS, 2019-2025
14 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $283 · 2021: $544 · 2022: $535 · 2023: $460 · 2024: $550 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $992.14 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $884.84 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.29 | 2019-2023 | Ofev |
| Amgen INC. | $203.38 | 2022-2025 | Tezspire |
| Insmed, INC. | $166.69 | 2019-2022 | |
| Genzyme Corporation | $142.50 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $113.73 | 2021-2024 | Dupixent |
| Mylan Specialty L.P. | $111.17 | 2020-2024 | Yupelri |
| Grifols USA, LLC | $97.21 | 2021-2025 | Prolastin-C Liquid |
| Electromed, INC. | $95.04 | 2019-2023 | Smartvest |
| Merck Sharp & Dohme LLC | $49.33 | 2019 | |
| Pfizer INC. | $44.33 | 2019 | |
| Olympus America INC. | $27.78 | 2024 | Spin Vision Video Processor |
| Paratek Pharmaceuticals, INC. | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.